EUCTR2008-002703-20-IT进行中（未招募）1 期
GR014: Randomized phase II study of NGR-hTNF in combination with standard chemotherapy versus standard chemotherapy alone in previously untreated patients with advanced non-small cell lung cancer (NSCLC. - NGR014
MOLMED0 个研究点目标入组 102 人开始时间: 2009年5月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 102
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1) Histologically or cytologically documented inoperable, locally advanced (stage IIIb with supraclavicular lymph node metastases or malignant pleural or pericardial effusion), metastatic (stage IV) or recurrent NSCLC. Mixed tumors should be categorized according to the predominant cell type. (2) Age ≥ 18 years (3) Life expectancy more than 3 months (4) ECOG performance status 0?1 (5) At least one unidimensionally measurable lesion (as per RECIST criteria) (6) Adequate baseline bone marrow, hepatic and renal function, defined as follows: - Neutrophils >1.5 x 10^9/L and platelets > 100 x 10^9/L - Bilirubin <1.5 x ULN - AST and/or ALT <2.5 x ULN in absence of liver metastasis - AST and/or ALT <5 x ULN in presence of liver metastasis - Serum creatinine <1.5 x ULN - Creatinine clearance (estimated according to Cockcroft?Gault formula) ≥ 50 ml/min (7) Patients may have had prior therapy providing the following conditions are met: - Radiation therapy: wash-out period of 28 days - Surgery: wash-out period of 14 days (8) Patients must give written informed consent to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1) Prior chemotherapy or treatment with another systemic anti-cancer agent (for example monoclonal antibody, tyrosine kinase inhibitor). (2) Patients must not receive any other investigational agents while on study (3) Patients with myocardial infarction within the last six (6) months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication (4) Uncontrolled hypertension (5) Prolonged QTc interval (congenital or acquired) (6) Patient with significant peripheral vascular disease (7) History or evidence upon physical examination of CNS disease unless adequately treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with standard medical therapy, or history of stroke). (8) Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol (9) Known hypersensitivity/allergic reaction or contraindications to human albumin preparations or to any of the excipients (10) Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol (11) Pregnancy or lactation. Patients ? both males and females ? with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of child-bearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration.
研究者
相似试验
进行中（未招募）
不适用
GR018: Randomized study based on administration of NGR-hTNF plus an anthracycline versus an anthracycline alone in platinum-resistant ovarian cancerAdvanced or metastatic platinum-resistant ovarian cancer patientsEUCTR2012-005745-20-ITMolMed S.p.A.24
进行中（未招募）
1 期
GR018: randomized study that schedules two treatments one with NGR-hTNF plus pegylated liposomal doxorubicin (PLD) and the other one with PLD in platinum-resistant ovarian cancerAdvanced or metastatic platinum-resistant ovarian cancer patientsMedDRA version: 13.1Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023613-61-ITMOLMED
进行中（未招募）
1 期
GR018:study based on a random assignment oftwo treatments that provide respectively the administration ofNGR-hTNF in combination with an anthracycline or onlysingle dose of anthracycline in patients with ovarian cancer resistant to platinum.EUCTR2010-023613-61-GBMOLMED133
进行中（未招募）
1 期
GR012: A phase II study of NGR-hTNF administered in combination with doxorubicin every 3 weeks in patients affected by advanced or metastatic ovarian cancer - NGR012Patients affected by advanced or metastatic ovarian cancer previously treated with platinum regimens (cis or carboplatin) plus paclitaxelMedDRA version: 14.1Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-000004-33-ITMOLMED
进行中（未招募）
不适用
GR010: A phase II study of NGR-hTNF administered as single agent every 3 weeks in patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one systemic therapeutic regimen - NGR010patients affected by advanced or metastatic malignant pleural mesothelioma previously treated with no more than one systemic therapeuticMedDRA version: 6.1Level: PTClassification code 10035605EUCTR2006-005993-39-ITMOLMED